Moleculin Biotech Stock Forum

$Moleculin Biotech (MBRX.US)$ how long it takes this company to make profit and start the growth, I know it is a long shot and company needs to complete all the regulations and safety procedures in order for the medicine to commercialized for the public and help people hopefully. Hope there won't be another reverse split in the future.

$Moleculin Biotech (MBRX.US)$
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model
Moleculin Biotech announced the publication of preclinical data demonstrating the significant activity of Annamycin in treating venetoclax-resistant acute myeloid leukemia (AML) cell lines. The study, presented at the American Society of Hematology Annual Meeting, revealed that Annamycin effectively targets both Cytarabine (...

$Moleculin Biotech (MBRX.US)$ New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
2 MINUTES AGO, 8:15 AM EST
VIA PR NEWSWIRE
Preclinical data accepted for online publication at ASH Annual Meeting reveal significant activity of Annamycin in Venetoclax resistant AML model
New preliminary clinical results show Annamycin plus Ara-C achieved 60% CR/CRi in subjects who were relapsed from or refractory to Venetoclax regimens; more than 4 times greater than published h...

$Moleculin Biotech (MBRX.US)$ Reuters· 3 mins ago
Moleculin Accelerates Planned Unblinded Data Readout for Miracle Phase 3 R/R Acute Myeloid Leukemia (Aml) Pivotal Trial to H2 2025

$Moleculin Biotech (MBRX.US)$
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
Moleculin Biotech (MBRX) has amended its Phase 3 MIRACLE trial protocol for Annamycin in combination with Cytarabine (AnnAraC) for treating relapsed/refractory AML. The amended protocol allows for earlier unblinding of preliminary efficacy data at 45 subjects in H2 2025, accelerating from the previous 2026 timeline. The trial will use...

$Moleculin Biotech (MBRX.US)$ Moleculin Receives Institutional Review Board Approval for Miracle Phase 3 Pivotal Trial of Annamycin in Combination With Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (Aml)

$Moleculin Biotech (MBRX.US)$ 🙀Why did the market stop🙈???

$Treasure Global (TGL.US)$ $Nuvve (NVVE.US)$ $Baosheng Media Group (BAOS.US)$ $iSpecimen (ISPC.US)$ $TELESIS BIO (TBIO.US)$ $Serina Therapeutics (SER.US)$ $Moleculin Biotech (MBRX.US)$ $Society Pass (SOPA.US)$ $Comstock Holding (CHCI.US)$
📊⚡️📊

$Moleculin Biotech (MBRX.US)$
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma